Lumexa Imaging (NASDAQ:LMRI) Now Covered by Truist Financial

Truist Financial assumed coverage on shares of Lumexa Imaging (NASDAQ:LMRI) in a research report sent to investors on Monday, MarketBeat Ratings reports. The brokerage issued a buy rating and a $18.00 target price on the stock.

Several other equities analysts also recently weighed in on LMRI. Raymond James Financial set a $17.00 price target on shares of Lumexa Imaging in a report on Monday, September 28th. KeyCorp started coverage on shares of Lumexa Imaging in a report on Thursday, September 24th. They issued an “overweight” rating and a $18.00 price objective on the stock. Deutsche Bank Aktiengesellschaft set a $16.00 target price on shares of Lumexa Imaging in a report on Thursday, August 13th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Lumexa Imaging in a report on Tuesday, September 22nd. Finally, Barclays increased their price target on Lumexa Imaging from $9.00 to $13.00 and gave the stock an “overweight” rating in a research report on Friday, August 28th. Two research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $16.40.

Lumexa Imaging Stock Performance

Shares of LMRI stock opened at $10.77 on Monday. The business has a fifty day moving average of $11.29 and a 200 day moving average of $10.27. Lumexa Imaging has a 1 year low of $6.45 and a 1 year high of $19.45. The company has a debt-to-equity ratio of 1.40, a current ratio of 1.44 and a quick ratio of 1.44. The firm has a market capitalization of $1.03 billion and a price-to-earnings ratio of -21.98.

Lumexa Imaging (NASDAQ:LMRI) last announced its quarterly earnings data on Wednesday, August 12th. The company reported $0.20 earnings per share for the quarter, beating analysts’ consensus estimates of $0.03 by $0.17. The firm had revenue of $264.16 million during the quarter. Lumexa Imaging has set its FY 2026 guidance at 0.710-0.770 EPS. As a group, research analysts expect that Lumexa Imaging will post 0.25 earnings per share for the current year.

Institutional Trading of Lumexa Imaging

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Bank of America Corp DE grew its stake in Lumexa Imaging by 1,855,116.7% in the 1st quarter. Bank of America Corp DE now owns 111,313 shares of the company’s stock valued at $957,000 after acquiring an additional 111,307 shares during the period. Renaissance Technologies LLC purchased a new stake in Lumexa Imaging in the 1st quarter worth $778,000. BlackRock Inc. acquired a new position in Lumexa Imaging during the second quarter worth $15,771,000. Brigade Capital Management LP acquired a new stake in shares of Lumexa Imaging in the second quarter valued at about $7,511,000. Finally, Janus Henderson Group PLC increased its stake in shares of Lumexa Imaging by 5.4% during the first quarter. Janus Henderson Group PLC now owns 2,100,356 shares of the company’s stock worth $18,063,000 after purchasing an additional 107,903 shares in the last quarter.

About Lumexa Imaging

Lumexa Imaging, Inc (NASDAQ: LMRI) is a U.S. healthcare services company focused on outpatient diagnostic imaging. The company operates and supports imaging centers that provide noninvasive services used to detect, diagnose and monitor medical conditions.

Its services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), mammography, ultrasound, X-ray and other diagnostic imaging procedures. Lumexa also works with radiologists and referring healthcare providers to deliver image interpretation and related clinical services.

The company’s operations are primarily located in the United States, serving patients through a network of outpatient imaging facilities and affiliated radiology practices.